RxDoctor Payments Data

Zaheer Ahmed, MD

Internal Medicine · Lowell, MANPI 1346289337

Payments from drug & device makers

$548in general payments, 2019–2025

Across 33 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$346
  • Sumitomo Pharma America, Inc.$46
  • Genmab U.S., Inc.$32
  • Astellas Pharma US Inc$25
  • Novartis$24
  • Blueprint Medicines Corporation$20
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$53397%
  • Education$153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$548 in reported general payments places this provider in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$197,013
Medicare patients
277
Services billed
1,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban299$174,181
JanuviaSitagliptin Phosphate145$102,908
XareltoRivaroxaban84$41,028
TrulicityDulaglutide24$29,034
MounjaroTirzepatide13$16,050
Combivent RespimatIpratropium/Albuterol Sulfate20$14,652
MyrbetriqMirabegron29$13,835
EntrestoSacubitril/Valsartan16$10,586
Breo ElliptaFluticasone/Vilanterol16$9,672
Atorvastatin Calcium815$8,541
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,488
Omeprazole365$8,342
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,000
Tresiba Flextouch U-100Insulin Degludec13$7,801
Metoprolol Succinate407$7,690

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$174,181299 claims
Astellas Pharma US IncMyrbetriq$25$13,83529 claims
AstraZenecaBreztri Aerosphere, Symbicort$20$13,77425 claims
NovartisEntresto$24$10,58616 claims
Sumitomo Pharma America, Inc.Gemtesa$46$3,85318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Lowell

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →